Business Context and Reporting Period
Oramed Pharmaceuticals Inc. filed this Form 8-K on July 11, 2013, reporting events occurring on July 10, 2013. The company, incorporated in Delaware with principal offices in Jerusalem, Israel, entered into definitive agreements to conduct a registered direct offering of its common stock.
Key Financial Metrics and Transaction Details
- Shares Offered: 658,144 shares of common stock.
- Offering Price: $7.00 per share.
- Gross Proceeds: Approximately $4.6 million (calculated from share count and price).
- Placement Agent Fees: Approximately $179,000 in cash compensation plus $30,000 for expense reimbursement.
- Net Proceeds: Expected to be approximately $4.2 million after deducting fees and estimated offering expenses.
- Placement Agent: Aegis Capital Corp.
Material Changes and Agreements
The filing discloses the entry into a Placement Agency Agreement and a Securities Purchase Agreement. These agreements facilitate the sale of the shares to various investors. The transaction represents a material capital raise intended to fund company operations, though the filing does not specify the exact allocation of funds beyond general offering expenses.
Guidance, Outlook, and Risks
- Closing Date: The offering is expected to close on or about July 16, 2013.
- Conditions Precedent: Closing is subject to the satisfaction of customary conditions and contingencies.
- Forward-Looking Statements: The company warns that the offering may not close if conditions are not met and that forward-looking statements are not guaranteed.
- Legal Opinion: An opinion regarding the legality of the issuance was provided by Zysman Aharoni Gayer and Sullivan & Worcester LLP.
Investor Verification Checklist
- Verify the actual closing of the offering on or after July 16, 2013.
- Confirm the final net proceeds received by the company after all expenses.
- Review the prospectus supplement filed with the SEC for detailed use of proceeds.
- Monitor subsequent filings for any dilution impact on existing shareholders.